Igor Gorbatchevsky

Prior to joining Celcuity, Dr. Gorbatchevsky worked for MEI Pharma (MEI), an oncology focused biopharmaceutical company, where he was the VP of Clinical Development. MEI's pipeline included zandelisib, an oral PI3K-delta inhibitor. He had previously served as the VP of Clinical Science at Iovance Biotherapeutics, as a Global Clinical Leader at Bayer Pharmaceuticals, and as a Senior Medical Director at Daiichi-Sankyo a global pharmaceutical company. At Bayer, his responsibilities included leadership of the Global Clinical Development Team for ALIQOPA (copanlisib), a pan-PI3K inhibitor approved by the FDA for treatment of patients with follicular lymphoma.